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BACKGROUND: Tumour growth is accompanied by gene and/or protein changes that may lead to peroxidation of the cell membrane
species and, hence, to the emission of volatile organic compounds (VOCs). In this study, we investigated the ability of a nanosensor
array to discriminate between breath VOCs that characterise healthy states and the most widespread cancer states in the developed
world: lung, breast, colorectal, and prostate cancers.
METHODS: Exhaled alveolar breath was collected from 177 volunteers aged 20–75 years (patients with lung, colon, breast, and
prostate cancers and healthy controls). Breath from cancerous subjects was collected before any treatment. The healthy population
was healthy according to subjective patient’s data. The breath of volunteers was examined by a tailor-made array of cross-reactive
nanosensors based on organically functionalised gold nanoparticles and gas chromatography linked to the mass spectrometry
technique (GC-MS).
RESULTS:The results showed that the nanosensor array could differentiate between ‘healthy’ and ‘cancerous’ breath, and, furthermore,
between the breath of patients having different cancer types. Moreover, the nanosensor array could distinguish between the breath
patterns of different cancers in the same statistical analysis, irrespective of age, gender, lifestyle, and other confounding factors.
The GC-MS results showed that each cancer could have a unique pattern of VOCs, when compared with healthy states, but not
when compared with other cancer types.
CONCLUSIONS: The reported results could lead to the development of an inexpensive, easy-to-use, portable, non-invasive tool that
overcomes many of the deficiencies associated with the currently available diagnostic methods for cancer.
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Cancer kills more than seven million people every year. The most
widespread cancers in the developed world, accounting for half of
the cancer deaths, are prostate, lung, and colorectal cancers for
men, and breast, colorectal, and lung cancers for women (Culter,
2008; Jemal et al, 2008). The prognosis of a cancer patient
improves considerably if the disease is discovered at an early stage,
when the tumour is still localised (Hirsch et al, 2001; Kalogerakos
et al, 2008). However, early detection is possible only through
widespread and screening, because of the asymptomatic onset of
the disease. The currently available techniques do not always fulfill
the requirements for reliable discrimination between cancer
patients and healthy subjects. For instance, the impact of
computed tomography screening on lung cancer mortality and
the benefit of the prostate-specific antigen blood test for prostate
cancer screening are uncertain (Culter, 2008). Screening methods
such as colonoscopy for colorectal cancer and mammography
for breast cancer are very reliable, but these methods are far from
ideal. Colonoscopy is invasive and extremely unpleasant to the
patient (Culter, 2008; Jemal et al, 2008). Mammography uses
X-rays which may cause radiation-induced mutations. In addition,
image quality depends on the breast structure, so that it is not
applicable to certain segments of the screening population, such as
young at-risk women (young women with a family history of
breast cancer and/or BRCA mutations) (Bermejo-Perez et al, 2008)
and women with dense breast tissue (B25% of women over the age
of 40 years) (Mandana, 2003; Andrew and Srinivasan, 2008).
The analysis of volatile organic compounds (VOCs) that are
linked to cancer is a new frontier in medical diagnostics because it
is non-invasive and potentially inexpensive (Amann et al, 2007;
Mazzone, 2008). The principle behind this approach is based on
cell biology. In particular tumour growth is accompanied by gene
and/or protein changes that may lead to peroxidation of the cell
membrane species and, hence, to the emission of VOCs (Singer
and Nicolson, 1972; Kneepkens et al, 1994; Alberts et al, 2002).
These VOCs can be detected either directly from the headspace of
cancer cells (Bajaj et al, 2009; Barash et al, 2009; Filipiak et al,
2010) or through exhaled breath (see Amann et al, 2007; Ligor
et al, 2008; Mazzone, 2008; Bajtarevic et al, 2009; Horvath et al,
2009; Ligor et al, 2009 and bibliography therein), as cancer-related
changes in the blood chemistry lead to measurable changes in the
breath by exchange through the lung (Horvath et al, 2009). In this
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based on organically functionalised gold nanoparticles (GNPs)
discriminates between breath VOCs of healthy controls and of
patients suffering from lung, breast, colorectal, and prostate cancers.
Moreover, we report on the ability of these GNP sensors to
distinguish between the breath patterns of different cancer types in
the same pattern analysis, irrespective of age, gender, lifestyle, and
other confounding factors. We find that these results compare
favourably with breath testing via a chemical analysis of the
constituent compounds by gas chromatography linked with mass
spectroscopy (GC-MS). The results reported in this study could lead
to the development of a cost-effective, easy-to-use, portable, non-
invasive tool that overcomes many of the deficiencies associated with
the currently available techniques used for the diagnosis of cancer.
MATERIALS AND METHODS
Test population
Breath samples were collected after signed consent from 96 volunteers
aged 30–75 years, who had not ingested coffee or alcohol for at least
12h. These were 30 primary lung cancer patients, 26 primary colon
cancer patients, 22 primary breast cancer patients, and 18 primary
prostate cancer patients and 22 healthy controls. All cancer patients
were tested directly after being diagnosed by conventional clinical
m e a n s( v a r i o u si m a g i n gt e c h n i q u es to locate the tumour and biopsy
for final diagnosis) and before chemotherapy and/or other cancer
treatments. No breath collection was carried out in the 4 days after
biopsy. The 22 healthy controls matched the tested cancer patients in
age and lifestyle. The clinical characteristics of the study population
are listed in Table 1. Additional breath samples were collected from
59 healthy volunteers, aged 20–75 years, for studying the effect of
various confounding factors (Table 2). All experiments were
approved by and performed according to the guidelines of Technion’s
committee for supervision of human experiments (Haifa, Israel).
Breath collection
Exhaled breath was collected in a controlled manner from
individuals with cancer in the same room/atmosphere and from
healthy subjects. The inhaled air was cleared of ambient
contaminants by repeatedly inhaling to total lung capacity for
3–5min through a mouthpiece (purchased from Eco Medics,
Duerten, Switzerland) that contains a filter cartridge on the
inspiratory port, thus removing 499.99% of exogenous VOCs
from the air during inspiration. Immediately after the lung
washout, subjects exhaled through a separate exhalation port of
the mouthpiece against 10–15cm H2O pressure to ensure closure
of the vellum so that nasal entrainment of gas is excluded.
Complementary experiments optimising the breath collection
procedure have shown that the sampling methodology simply
measures alveolar breath uncontaminated by upper airways release
and exogenous compounds. Exhaled breath is a mixture of alveolar
air and respiratory dead space air. The dead space was
automatically filled into a separate bag and the alveolar breath
into a 750ml Mylar sampling bag (purchased from Eco Medics). It
should be emphasised that the described breath collection is a
single-step process that does not require the volunteer to take care
of changing between the dead space and alveolar breath bags. The
Mylar bags used in this study are made from polyvinyl fluoride,
which is chemically inert with respect to most compounds in the
breath. The Mylar bags were re-used and thoroughly cleaned
before each use with flowing N2 (99.999% purity) gas for 5–8min
(Notably, GC-MS/solid-phase microextraction (SPME) has shown
that this purification process eliminates 498% of contaminants
and/or VOCs from the previous sample tested in a specific Mylar
bag.). At least two bags were collected per test person for analysis
with GC-MS and/or for analysis with a nanosensor array based on
organically functionalised GNPs – see below. All bags were
analysed within 4 days from the time of breath collection, much
before the allowed 3-weeks storage period, after which, according
to our control experiments, the samples might start to deteriorate.
Design and fabrication of the nanosensor array
Monolayer-capped 5nm GNPs were synthesised by a modified two-
phase method (Brust et al, 1995), combined, if necessary, with a
ligand-exchange procedure. Dodecanethiol, 4-methoxy-toluenethiol,
hexanethiol, 11-mercapto-1-undecanol, decanethiol, octadecanethiol,
tert-dodecanethiol, 1-butanethiol, 2-ethyl-hexanethiol, 3-methyl-1-
butanethiol, 2-mercaptobenzoxazole, 11-mercapto-1-undecanol,
2-mercapto-benzyl alcohol, and 3-methyl-1-butanethiol (all pur-
chased from Sigma-Aldrich, Rehovot, Israel) were used as organic
capping layers. The GNP synthesis was described in detail in the
study by Peng et al (2009). In all, 10 pairs of circular inter-digitated
gold electrodes were deposited by an electron-beam evaporator
TFDS-870 (VST Ltd, Petah Tiqwa, Israel) on device quality silicon
wafers capped with 300nm thermal oxide (purchased from Silicon
Quest International Inc., Santa Clara, CA, USA). The outer
diameter of the circular electrode area was 3000mm; the gaps
between two adjacent electrodes and the width of each electrode
were both 20mm. The functionalised GNPs were dispersed in
toluene by sonication and drop cast onto the electrodes. While still
coated with solution, the substrate was blown dry with N2. This
process was repeated several times to yield the desired resistance
of B1MO. The device was dried for 2h at room temperature in an
ambient atmosphere and then baked overnight at 501Ci na
vacuum oven. Figure 1A shows a schematic representation of the
device. Overall, 14 GNP sensors with different organic function-
alities were mounted onto a custom PTFE circuit board to form the
nanosensor array.
Breath testing using the GNP sensor array
The developed nanosensor array was placed inside a home-made
stainless steel test chamber with a volume of o100cm
3. The
sampling system first evacuated the chamber, then delivered a
pulse of breath from the sample bags to the GNP sensors, and then
evacuated the chamber again. In a typical experiment, signals of
the GNP sensor array were collected for 5min in vacuum, then for
5min during breath exposure, and then again for 5min in vacuum.
The cycles were repeated 3–5 times to test reproducibility. Each
sensor of the array underwent a reversible change in electrical
resistance when exposed to the sample breath. The responses of
the different sensors were unique because of the chemical diversity
of the sensor materials. An Agilent Multifunction switch 34980
(Agilent Technologies Ltd, CA, USA) controlled by USB was used
to select the active GNP sensor and measure the corresponding
resistance at a given time. The electrical resistance of the GNP
sensors was measured using a device analyser using integration
times that span at least two power line cycles. The entire system
was computer controlled.
Signals collected from all sensors in the array were analysed
using standard principal component analysis (PCA) and cluster
analysis (Peng et al, 2008, 2009; Roeck et al, 2008). Principal
component analysis is an effective method to reduce multi-
dimensional data space to its main components and, therefore
improves the human perception ability of the data. It determines
the linear combinations of sensor values so that the maximum
variance between all data points can be obtained in mutually
orthogonal dimensions. This results in the largest variance
between sensor values from the first principal component and
produces decreasing magnitudes of variance from the second to
the third principle components and so on.
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The collected breath was chemically analysed, that is, its
constituent compounds were identified, using GC-MS (GC-
6890N; MS-5975; Agilent Technologies Ltd), combined with SPME.
The SPME was used for pre-concentrating VOCs in breath
samples. A manual SPME holder with an extraction fibre was
inserted into the Mylar bag for 20–30min before being delivered
to the GC-MS. We used a commercially available fibre with poly-
dimethylsiloxane-divinylbenzene coating obtained from Sigma-
Aldrich. The extracted fibre in the manual SPME holder was
inserted into the injector of the GC (splitless mode). We used the
following oven profile: 601C, 2min, 81C per min to 1001C, 151C per
min to 1201C, 81C per min to 1801C, 151C per min to 2001C, 81C
per min to 2251C. A capillary column H5-5MS 5% phenyl methyl
siloxane (30m length, 0.25mm i.d., 0.25mm thickness, from
Agilent Technologies Ltd) was used. The column pressure was
set at 8.22p.s.i., and the initial flow rate was 1.0ml per min. The
molecular structures of VOCs were determined by a spectral
library match (and not by retention time using calibration
mixtures) using the standard modular set. The VOCs common
for 480% of the healthy and cancer samples, as well as their
abundance with experimental error, were identified using the
Automated Mass Spectral Deconvolution and Identification System
(AMDIS) software. Out of the common VOCs, those that showed
no overlap in abundance (taking into account their experimental
errors) between the studied groups were determined. The PCA
algorithm was applied to this choice of VOCs.
RESULTS AND DISCUSSION
This study was conducted in four phases. In the first phase,
exhaled alveolar breath was collected from 177 volunteers aged
20–75 years (lung, colon, breast, and prostate cancer patients and
healthy controls; Tables 1 and 2), using an ‘offline’ method
described by Peng et al (2009). This method effectively separates
endogenous VOCs in the breath from exogenous VOCs, and
excludes nasal entrainment. Endogenous VOCs are generated by
cellular biochemical processes in the body and, thus, may provide
insight into the body’s function (Kneepkens et al, 1994; Baubach
et al, 2005), whereas exogenous VOCs are adsorbed from the
environment (Baubach et al, 2005). All cancer patients were tested
immediately after being diagnosed by conventional clinical means,
and before any treatment.
Table 2 Clinical characteristics of the test population for 59 healthy volunteers, aged 20–75 years, for studying the effect of various confounding factors
Total number of subjects per age group (years)
Age group 20–29 30–39 40–49 50–59 60–69 70–75 Total
Number 12 13 8 11 14 1 59
Gender
Male 3 9 2 5 9 1 29
Female 9 4 6 6 5 30
Smoker
No
a 91 2 8 91 1 15 0
Yes
b 31 23 9
Family cancer history
No 6 6 2 6 4 24
Yes 6 7 6 5 9 1 34
Unknown 11
Drug treatment
No 11 13 6 5 2 37
Yes 1 2 6 12 1 22
Chronic disease
No 10 12 7 4 4 37
Yes 2 1 1 7 10 1 22
Pollutant exposure
No 7 10 5 7 8 1 38
Yes 5 3 3 4 6 21
Allergies
No 9 11 3 8 10 41
Yes 3 2 5 3 4 1 18
Food additive
No 11 13 5 10 12 1 52
Yes 1 3 1 2 7
Place of birth
Israel 11 11 7 9 8 46
Other 1 2 1 2 6 1 13
No inclusion/exclusion criteria were applied in this group.
aThe non-smoker group may include former smokers and passive smokers.
bThe smoker group includes both heavy and
light smokers.
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nanosensors, based on 5-nm GNPs (Haick, 2007; Barash et al, 2009;
Peng et al, 2009) with different organic functionalities (see the
‘Materials and Methods’ section), and tested its feasibility for
simultaneous detection of primary lung, colon, breast, and
prostate cancers. Figure 1A shows a schematic representation of
the device. Arrays of broadly cross-reactive GNP sensors are
ideally suited to trace the cancer odour prints directly, without
identifying the constituent VOCs (Roeck et al, 2008). The GNP
sensors combine the robustness and processing ease of inorganic
materials with the sensitivity and chemical selectivity of certain
organic molecules to cancer biomarker VOCs (Haick, 2007; Jain
et al, 2007). Some of the GNP sensors have detection limits of
1–5p.p.b. to typical cancer biomarkers (Peng et al, 2009), whereas
the others have a detection limit down to B10p.p.t. The apparent
detection limit and sensitivity of these sensors were demonstrated
for different compounds elsewhere (Barash et al, 2009; Peng et al,
2009). Every sensor of the array undergoes a rapid and fully
reversible change in electrical resistance when exposed to the
breath sample. Some of the GNP sensors show a positive resistance
change, others show a negative resistance change (Figure 1B–D).
The sensing mechanism in GNP thin films is still subject to
controversy (Haick, 2007). In most cases, the responses are unique
because of the chemical diversity of the sensor materials. Each
sensor responds to various odourants, that is, to an individual
subset of VOCs in a breath sample. This method distinguishes the
odour print resulting from the constituent VOCs directly, without
identifying the individual compounds. This black-box approach is
essentially different from the chemical analysis of a breath sample
by GC-MS or related methods (see below). The subtle differences
in the chemical composition that distinguish the breath of healthy
individuals, and lung, breast, colorectal, and prostate cancer
patients from one another lead to measurable changes in the
responses of the individual GNP chemiresistors (Figure 1B–D).
Signals collected from the 14-sensors-array after exposure to the
breath of representative subjects from the 5 different test groups
were analysed using standard PCA (Roeck et al, 2008; Peng et al,
2009). Principal component analysis is an effective method to
improve human perception of experimental data by reducing the
multidimensional data space to its main components (for more
details, see the ‘Materials and Methods’ section). Figure 2 shows
the maps of the first two principal components (PC1 and PC2) for
each signal, which account for 488% variance. We analysed
(1) lung cancer patients and healthy subjects only, (2) colon cancer
patients and healthy subjects only, (3) breast cancer patients and
healthy subjects only, (4) prostate cancer patients and healthy
subjects only, and (5) lung, breast, colorectal, and prostate cancer
patients and healthy subjects together (patient data in Table 1).
A very good separation was achieved in the principal component
space between the patterns of healthy controls and of patients
suffering from lung, colon, and breast cancers, as seen in Figure
2A–C. Complementary analysis has not shown any correlation
between the classification quality and the age of the sensors. The
cluster of prostate cancer patients (Figure 2D) slightly overlaps
with the healthy cluster, probably owing to the fact that many of
the prostate cancer test groups have stage I cancer. Moreover, we
were able to distinguish between the patterns of the four different
cancers in the same principal component plot, with only minimal
overlap between the prostate cancer and healthy clusters, as seen in
Figure 2E. Notably, although we used the same study populations
in Figure 2A–E, the clusters appear differently in principal
component space, because the input data for the statistical
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Figure 1 (A) Schematic representation of the GNP sensors in this study (not drawn to scale). The sensors were formed by successively drop casting the
solutions of the molecularly modified GNP solutions onto 10 pairs of pre-prepared Ti/Au-inter-digitated electrodes. The left inset in the sensor’s schematics
shows a tunnelling electron micrograph (TEM) of the NPs, which connects the electrodes and forms multiple paths between them. The right inset of the
sensor’s schematics shows schematics of films based on molecularly modified GNPs. In these films, the metallic particles provide the electric conductivity, and
the organic film component provides sites for the sorption of analyte (guest) molecules. In addition to their role as an adsorptive phase, the presence of well-
defined organic spacers (i.e., capping molecules) allows a control over the inter-particle distance, and thereby, obtaining nearly uniform inter-particle
distances in the composite films. This allows achieving controlled signal and noise levels. Typical resistance responses, DR/Rb, of three GNP sensors
functionalised with (B) 2-ethylhexanethiol, (C) decanethiol, and (D) 2-mercaptobenzoxazole, upon exposure to breath of a lung cancer (LC), colon cancer
(CC), breast cancer (BC), and a prostate cancer (PC) patients, as well as a healthy subjects, are shown as representative examples. Rb is the baseline
resistance of the GNP sensor in vacuum, and DR is the baseline-corrected steady-state resistance change upon exposure of the GNP sensor to the breath
sample.
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cancer site is a major step towards the development of a robust
breath test for cancer. This study was conducted using a relatively
small test population, and therefore constitutes only a proof of
concept. A wider clinical study would be necessary to confirm the
criteria for distinguishing different cancers, and to establish
criteria for distinguishing cancer subtypes and stages (Rubin
et al, 1997). It is reasonable to expect that clusters for a larger
study population would be less well defined and some overlap
would occur. In turn, cluster separation could be improved again
by developing the GNP sensor array further while maintaining
minimum sensitivity to potential confounding effects of
common breath metabolites (such as ammonia (CAS: 7664-41-7),
acetone (CAS: 67-64-1), methanol (CAS: 67-56-1), and ethanol
(CAS: 64-17-5)), which, based on GC-MS/SPME, were found in
approximately 20–30% of the examined patients. The iterative
improvement in the sensor array while expanding the study
population would eventually yield an optimised device. The
use of organically functionalised GNPs allows tailoring the
properties of the constituent sensors to tune their sensitivity
to cancer VOCs.
In the third phase, we compared our proposed method of
breath testing using a GNP sensor array with breath analysis
through GC-MS. GC-MS is often used for identifying biomarker
VOCs of diseases, including breast (Phillips et al,2 0 0 3 )a n dl u n g
cancers (Ligor et al, 2008, 2009; Mazzone, 2008; Bajtarevic et al,
2009; Peng et al, 2009), but has not been applied to distinguish
between different types of cancer. In this study, we combined
GC-MS with SPME. GC-MS identifies the VOCs that can serve as
cancer biomarkers in breath samples and determines their relative
compositions (Ouyang and Pawliszyn, 2006; Amorimb and Cardeal,
2007). SPME is a convenient method to pre-concentrate cancer
biomarker VOCs in the breath samples, because GC-MS per se is not
sensitive enough to concentrations below the p.p.m. (part-per-
million) level. It must be noted that solid-phase extracts include
only part of the constituent compounds, and, therefore selectively
enhance the signals of certain biomarkers, whereas it potentially
misses others (Barash et al, 2009). Hence, it is likely that not all of
the cancer biomarker VOCs in the breath samples, to which the
array of GNP sensors responded, were identified. For example, there
is some evidence that formaldehyde is elevated in the urine (and
hence blood/breath) of prostate cancer patients (Spanel et al,1 9 9 9 )
and nitrosamines in the flatulence (and perhaps in breath as is gut-
produced methane) of bowel cancer patients (Amann et al, 2007).
These may be the major compounds that are activating the sensors
but they are not picked up by GC-MS/SPME.
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different VOCs per breath sample (Peng et al, 2009), with 487%
reproducibility for a specific volunteer that was examined multiple
times over a period of 6 months. Using forward stepwise
discriminant analysis, we identified a number of VOCs, which
are present in 480% of lung cancer patients and healthy subjects
(33 VOCs) (Peng et al, 2009), colon cancer patients and healthy
subjects (39 VOCs), breast cancer patients and healthy subjects
(54 VOCs), and prostate cancer patients and healthy subjects
(36 VOCs). Some of these common VOCs occur in distinctly
different concentration ratios, so that the change in their overall
composition can be used as a cancer biomarker (Peng et al, 2009).
Owing to the large experimental scatter in their abundance, not all
common VOCs are suitable for distinguishing between healthy
controls and cancer patients. We selected the most suitable ones,
for which there was no overlap in abundance between healthy
controls and cancer patients – six VOCs for lung cancer, six VOCs
for colon cancer, five VOCs for breast cancer, and four VOCs for
prostate cancer (see Figure 3A–D and figure caption therein). To
the best of our knowledge, most of the VOCs reported in this study
appear for the first time in the literature. The exceptions are the
two lung cancer VOCs: VOC 1 (1-methyl-4-(1-methylethyl)
benzene; m/z¼119; CAS: 99-87-6), which was reported earlier by
Phillips et al (1999a,b), Poli et al (2005), and Ligor et al (2009);
and VOC 2 (toluene; m/z¼91; CAS: 108-88-3), which was reported
earlier by Poli et al (2005) and Ligor et al (2009).
From the data presented in Figure 3, we determined the
characteristic odour prints of the studied cancer types through
PCA and cluster analysis (see Supporting Information, Supple-
mentary Figure S1A–D). As can be seen in the figure, good
discrimination can be achieved between lung cancer patients and
healthy subjects (Supporting Information, Supplementary Figure
S1A) and between breast cancer patients and healthy subjects
(Supporting Information, Supplementary Figure S1C). The clusters
for prostate cancer patients and healthy subjects are closer
together and the signature of one prostate cancer patient falls
into the healthy cluster (Supporting Information, Supplementary
Figure S1D). The sensitivity of this method to colon cancer
is slightly lower: B30% of the colon cancer patient signatures are
found in the healthy cluster (Supporting Information, Supplemen-
tary Figure S1B). It must be noted that the GNP array achieved the
best separation for colon cancer patients and healthy subjects,
illustrating the fundamental difference in the two approaches
(Kushch et al, 2008). While achieving reasonable discrimination
between healthy controls and patients suffering from one specific
cancer, we were unable to determine suitable representative VOCs
for distinguishing all cancers. This is because the GC-MS analysis
did not yield compounds without overlap in abundance for lung,
colon, breast, and prostate cancers and healthy test groups
together. To achieve separation between the five study groups,
we performed the PCA using all 16 VOCs used before for the
successful separation of each cancer type from healthy controls,
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Figure 3 Pre-selection of the GC-MS input data for PCA: The most suitable VOCs were selected for distinguishing between healthy subjects and patients
suffering from a specific cancer: (A) 6 of 33 common VOCs for lung cancer (LC); (B) 6 of 39 common VOCs for colon cancer (CC); (C) 5 of 54 common
VOCs for breast cancer (BC); (D) 4 of 36 common VOCs for prostate cancer (PC). The abundance of the choice VOCs for healthy controls and cancer
patients does not overlap (cf. error bars). (E) The entire 16 VOCs used in (panels A–D) for separating each type of cancer from the healthy controls.
It must be noted that the GC-MS analysis did not yield compounds without overlap in abundance for lung cancer, breast cancer, colorectal cancer, and
prostate cancer and healthy test groups together. The VOCs were tentatively identified as: VOC 1¼1-methyl-4-(1-methylethyl)benzene (m/z¼119; CAS:
99-87-6); VOC 2¼toluene (m/z¼91; CAS: 108-88-3); VOC 3¼dodecane (m/z¼57; CAS: 112-40-3); VOC 4¼3,3-dimethyl pentane (m/z¼43;
CAS: 562-49-2); VOC 5¼2,3,4-trimethyl hexane (m/z¼43, CAS: 921-47-1); VOC 6¼1,10-(1-butenylidene)bis benzene (m/z¼208, CAS: 1726-14-3);
VOC 7¼1,3-dimethyl benzene (m/z¼91, CAS: 108-38-3); VOC 8¼1-iodo nonane (m/z¼43; CAS: 4282-42-2); VOC 9¼[(1,1-dimethylethyl)thio] acetic
acid (m/z¼57; CAS: 24310-22-3); VOC 10¼4-(4-propylcyclohexyl)-40-cyano[1,10-biphenyl]-4-yl ester benzoic acid (m/z¼257; CAS: 82406-83-5); VOC
11¼2-amino-5-isopropyl-8-methyl-1-azulenecarbonitrile (m/z¼224; CAS: 93946-48-6); VOC 12¼5-(2-methylpropyl)nonane (m/z¼57; CAS: 62185-53-9);
VOC 13¼2,3,4-trimethyl decane (m/z¼43; CAS: 62238-15-7); VOC 14¼6-ethyl-3-octyl ester 2-trifluoromethyl benzoic acid (m/z¼173;
NIST: 282650); VOC 15¼p-xylene (m/z¼91; CAS: 106-42-3); and VOC 16¼2,2-dimethyl decane (m/z¼57; CAS: 17302-37-3). m/z indicates the
major target mass.
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group (Figure 3E). It must be noted that one compound used to
distinguish between breast cancer and healthy states (decane 2,3,
4-trimethyl; CAS: 62238-15-7), was found in o80% of the breath
samples in one or more of the other study groups. Hence, it was
not considered in this study. Supplementary Figure S1E of the
Supporting Information shows that the clusters of the five study
groups are also strongly overlapping for the second set of selected
VOCs. It must be noted that for any other arbitrary choice of
representative VOCs, the abundances for the five study groups
would overlap. Hence, it is not reasonable to expect a better
discrimination through another choice of representative VOCs.
Several studies using GC-MS have shown that age, gender,
lifestyle, nutrition, medication, smoking habits, and other
confounding factors affect the chemical composition of the breath
(Mendis et al, 1994; Lechner et al, 2006; Kushch et al, 2008) and, as
a result, the sensitivity and specificity of the diagnosis. Therefore
we tested, in the fourth phase of this study, whether the same
applies for GNP sensors array as well. We examined breath
samples from a heterogeneous group of 59 healthy volunteers aged
20–75 years (Table 2). We found that none of the following
confounding factors affected the sensor array output: gender, age,
ethnic origin, family cancer history, intake of food additives, drug
treatment, exposure to environmental toxins, and smoking habits
(Figure 4). In contrast, we could trace and identify by GC-MS/
SPME a multitude of VOCs, which can be linked to these
confounding factors. For example, 2,6,11-trimethyl-dodecane
(CAS: 31295-56-4) was found in 80% of the males, but in none
of the females participating in the test; 3,7-dimethyl-undecane
(CAS: 17301-29-0) was found in 100% of the subjects with allergies,
but only in 9% of the subjects without allergies. The presence of
various non-cancer-related breath VOCs in a heterogeneous study
population might obscure cancer biomarker VOCs, and might be
in part responsible for the observed inferior discriminative power
of GC-MS/SPME compared with the GNP sensor array.
SUMMARY AND CONCLUSIONS
Breath analysis with a GNP sensor array compared favourably with
breath analysis using GC-MS because: (1) no pre-treatment of the
breath samples, such as pre-concentration or de-humidification, is
required; (2) the test itself is fast, easy to carry out, and does not
necessarily require a trained operator; (3) no time-consuming
pre-selection of the experimental data is necessary before the
statistical analysis to achieve separation between the tested groups;
(4) the different cancers form clusters well separated from one
another and from the healthy clusters; and (5) the GNP sensor
array is insensitive to various confounding factors, which strongly
affect the chemical composition of the breath. The VOC signatures
of the different types of cancer, with almost no overlapping among
them, could lead to the development of a cost-effective, easy-to-use,
portable, and non-invasive diagnostic tool for detecting lung, breast,
colorectal, and prostate cancers through a single breath test, which
could have a significant impact on cancer mortality through
improved widespread screening. T h es a m et o o lm i g h ta l s oh e l pt o
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Figure 4 PCA plots of the GNP sensor array exposed the breath of 59 healthy subjects. Normally, two samples of each subject were analysed. Plots were
analysed according to different characteristics: age, gender, place of birth, ethnicity, family cancer history, intake of food additives, drug treatment, work
pollution, and smoking habits (see Table 2). The first two principal components depicted contained 490% of the total variance in the data.
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sdistinguish between primary cancer vs metastases, rapidly monitor
therapy success and response to the administered treatment, as well
as to detect early recurrence in an annual routine survey.
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